- $74.76m
- $39.62m
Annual balance sheet for Immunic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 127 | 86.9 | 116 | 46.7 | 35.7 |
| Net Total Receivables | 0.295 | 2.15 | 2.66 | 1.37 | 0.684 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 134 | 105 | 126 | 52.5 | 39.3 |
| Net Property, Plant And Equipment | 1.1 | 1.1 | 1.85 | 1.76 | 1.54 |
| Net Goodwill | |||||
| Other Long Term Assets | |||||
| Total Assets | 168 | 139 | 128 | 54.3 | 40.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.4 | 11.4 | 13.1 | 24.7 | 22.2 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 9.08 | 12 | 14.1 | 25.4 | 22.4 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 159 | 127 | 114 | 28.9 | 18.4 |
| Total Liabilities & Shareholders' Equity | 168 | 139 | 128 | 54.3 | 40.9 |
| Total Common Shares Outstanding |